Shutterstock.com
Since 2014, there have been several reports linking sildenafil (Viagra), a phosphodiesterase inhibitor (PDE5i), to an increased risk of melanoma.
In a paper published in the Journal of the National Cancer Institute
[1] (online, 19 May 2017), researchers carried out a meta-analysis on data from three case-control studies and two cohort studies, which were carried out between 1998 and 2016, involving a total of 866,049 men.
They found that men exposed to PDE5i had an increased risk of melanoma (relative risk 1.11, 95% confidence interval 1.02–1.22). However, there was a lack of dose response or clear relationship to melanoma staging, nor was there specificity for the type of skin cancer which, the researchers say, suggests against a causal relationship.
The observed association is possibly due to confounding factors, most likely sunlight exposure, the team conclude.
References
[1] Loeb S, Ventimiglia E, Salonia A et al. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst 2017;109. doi: 10.1093/jnci/djx086
You may also be interested in
Black people with cancer more likely to experience heart damage with chemotherapy, study results show
Thousands of NHS patients with prostate or breast cancer eligible for new targeted treatment
